Who
Neil William Aubuchon
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Viking Therapeutics.
In numbers
- Trades disclosed
- 4
- Buys
- 1
- Sells
- 0
- Bought
- $300K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Jan 2026
- Last trade
- 10 Mar 2026
- Last filed
- 10 Mar 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Mar 2026filed 10 Mar 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Bought | $150K4,475 at $33.50 | filing |
| 10 Mar 2026filed 10 Mar 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Bought | $150K4,475 at $33.50 | filing |
| 12 Jan 2026filed 26 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 12 Jan 2026filed 26 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Neil William Aubuchon; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.